First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

ESMO Open

article

A. Ortega-Franco¹  C. Ackermann²  L. Paz-Ares³  R. Califano¹ 

[1] Department of Medical Oncology, The Christie NHS Foundation Trust;Department of Medical Oncology;Department of Medical Oncology, Hospital Universitario 12 de Octubre

关键词: small-cell lung cancer;    immune checkpoint inhibitors;    lung cancer;    atezolizumab;    durvalumab;   

DOI  :  10.1016/j.esmoop.2020.100003

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Small-cell lung cancer (SCLC) is an aggressive and rapidly growing disease with poor prognosis. Despite intense efforts to improve clinical outcomes, platinum/etoposide chemotherapy has remained the most effective regimen for first-line extensive disease SCLC for decades. The addition of immune checkpoint inhibitors, and specifically programmed death-ligand 1 inhibitors, to standard platinum/etoposide, significantly improves survival and represents a promising advance in this field. However, identification of a predictive biomarker to refine patient selection is an area of unmet need. Further understanding of tumour immunity and mechanism of resistance is required to design novel strategies that improve survival. In this review, we describe recent developments and future directions on first-line immune checkpoint blockade for extensive disease-SCLC.

【 授权许可】

CC BY|CC BY-NC-ND